๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nagpur
Clinical trial register · India

Clinical Trials in Nagpur, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Eli Lilly and Company13 Bristol-Myers Squibb12 Novo Nordisk A/S9 Novartis Pharmaceuticals6
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Nagpur

125 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Belagavi, Nagpur, Pune, New Delhi, Dehradun, Kolkata, Ahemdabad, Bangalore
2026-12-16
Not yet open
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
NCT07459543Unresectable Melanoma, Metastatic Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 4
40
Nashik, Mumbai, Navi Mumbai, Pune, Bhubaneswar, Chennai, Nagpur, New Delhi
2026-11-15
Not yet open
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
NCT07840105Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
DrugCeftazidime-avibactam
Wockhardt
Phase 2
279
Visakhapatnam, Raipur, Belagavi, Mandya, Mysore, Kozhikode, Nagpur, Nashik
2026-09-30
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Belgavi, Kozhikode, Nashik, Sakri, Kolkata, Nagpur, New Delhi
2026-09-11
Not yet open
Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled Trial
NCT07762599Apical Periodontitis, Post Endodontic Pain, Periapical Healing, Inflammatory Biomarkers
All India Institute of Medical Sciences
Not applicable
50
Nagpur
2026-08-30
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Aligarh, Baroda, Guntur, Hubli, Jaipur, Mysore, Nagpur, Trivandrum
2026-08-26
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461Type 2 Diabetes
DrugSurvodutide
Boehringer Ingelheim
Phase 3
600
Ahmedabad, Bhubaneswar, Cuttack, Hyderabad, Afzalgunj, Kolhฤpur, Lucknow, Nagpur, Nashik
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugAZD6234
AstraZeneca
Phase 3
1,500
Bangalore, Indore, Kolkata, Nagpur, Pune, Siliguri, Visakhapatnam
2026-08-20
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
Ahmedabad, Nagpur, Nerul, Bhubaneswar, Kolkata
2026-06-02
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Guntur, Ahmedabad, Vadodara, Belagavi, Mangalore, Manipal, Kochi, Nagpur
2026-05-11
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guntur, Vijayawada, Bengaluru, Kochi, Mumbai, Nagpur, Delhi, Bhubaneswar
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guntur, Vijayawada, Bengaluru, Kochi, Mumbai, Nagpur, New Delhi, Delhi
2026-05-05
Not yet open
Comparative Evaluation of Calcium Silicate-doped Treated Dentin Matrix and Mineral Trioxide Aggregate as Miniature Pulpotomy Biomaterials in Deep Carious Lesions
NCT07302438Reversible Pulpitis, Deep Carious Lesions
All India Institute of Medical Sciences
Not applicable
56
Nagpur
2026-04-25
Recruiting
Caffeine for Hypoxic Ischemic Encephalopathy
NCT06855108Hypoxic Ischemic Encephalopathy (HIE)
NICHD Global Network for Women's and Children's Health
Phase 3
830
Belagavi, Nagpur
2026-04-08
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Eluru, Goraj, Pลซlakkลd, Aurangabad, Mumbai, Nagpur, Dwarka, New Delhi
2026-03-16
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Eluru, Visakhapatnam, Goraj, Mumbai, Nagpur, Dwarka, Hyderabad, Delhi
2026-03-12
Recruiting
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
NCT07171983Rheumatoid Arthritis
Bristol-Myers Squibb
Phase 1
46
Hyderabad, Ahmedabad, Bangalore, Mysuru, Nagpur, Pune, Bhubaneswar, Secunderabad
2026-02-27
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Bengaluru, Bhubaneswar, Guntur, Nagpur, New Delhi, Pune, Raipur, Rishikesh
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Guntur, Guwahati, Hyderabad, Mandya, Mumbai, Mysore, Nagpur, Nashik
2026-02-06
Recruiting
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
NCT06531798Moderate to Severe COPD
AstraZeneca
Phase 4
150
Dalgate, Drugjan, Hyderabad, Lucknow, Nagpur, New Delhi
2026-01-30
Recruiting
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA
Phase 3
400
Vijayawada, Guwahati, Mumbai, Nagpur, Navi Mumbai, Madurai, Bฤซbฤซnagar, Lucknow
2026-01-23
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
NCT06723392Preterm Birth, Small for Gestational Age (SGA), Stillbirth, Bacteriuria (Asymptomatic) in Pregnancy
NICHD Global Network for Women's and Children's Health
Phase 3
1,134
Belagavi, Nagpur
2025-12-08
Active, closed
Comparative Evaluation of Endodontic Instrumentation Kinematics and Cryotherapy on Post-endodontic Pain and Periapical Healing
NCT07500870Post Endodontic Pain, Periapical Healing
All India Institute of Medical Sciences
Not applicable
60
Nagpur
2025-12-04
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Nagpur, Nashik, Pune
2025-11-25
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Ahmedabad, Gurugram, Bengaluru, Mumbai, Nagpur, New Delhi, Howrah
2025-11-05
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Aligarh, Jaipur, Kolkata, Kozhikode, Nagpur, Nashik, New Delhi, Rishikesh
2025-10-31
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Hyderabad, Rajkot, Nagpur, Jaipur, Kolkata
2025-09-29
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Mumbai, Nagpur, New Delhi, Chennai, Hyderabad, Varanasi
2025-09-11
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belagavi, Belgavi, Jaipur, Kanpur, Kozhikode, Lucknow, Nagpur, Nashik
2025-09-02
Active, closed
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
NCT07109297RSV Immunization
DrugNirsevimab
Sanofi
Phase 4
110
Bengaluru, Jaipur, Kolkata, Nagpur, New Delhi, Pune, Vizianagaram
2025-07-31
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Ahmedabad, Bengaluru, Bikaner, Kanpur, Kolkata, Maharashtra, Nagpur, Nashik
2025-07-22
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
DrugVerekitug
Upstream Bio Inc.
Phase 2
666
Hyderabad, Nellore, Vijayawada, Gurgaon, Rohtak, Kolhฤpur, Nagpur, New Delhi
2025-07-02
Not yet open
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
NCT07017036Primary Immunodeficiency Diseases (PID)
Virchow Group
Phase 3
44
Nagpur, Jaipur
2025-07-01
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Vadodara, Kochi, Mumbai, Nagpur, New Delhi, New Dehli, Ludhiana, Dehradun
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Vadodara, Nagpur, New Delhi, New Dehli, Vijayawada, Chennai, Hyderabad, Dehradun
2025-06-27
Active, closed
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517Multiple Myeloma
DrugTeclistamab
Johnson & Johnson Private Limited
Phase 4
75
Bangalore, Bengaluru, Chandigarh, Jaipur, Kolkata, Mumbai, Nagpur, New Delhi
2025-05-22
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Ahmedabad, Kolkata, Mumbai, Nagpur, Nashik, Pune, Vadodara, Varanasi
2025-03-19
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Guntur, Ahmedabad, Mangaluru, Mumbai, Nagpur, Nashik, Ajmer, Lucknow
2025-03-11
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
DrugEtavopivat
Novo Nordisk A/S
Phase 3
510
Guwahati, Raipur, Dohad, Surat, Vadodara, Mysuru, Kozhikode, Nagpur
2025-02-17
Recruiting
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
NCT06755450Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited
Phase 1
40
Vadodara, Jhajjar, Bangalore, Aurangabad, Nagpur, Pune, Satara, Thane
2025-01-15
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Nagpur, New Delhi, Rohtak
2024-11-12
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Mohali, Nagpur, New Delhi
2024-10-14
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Calicut, Hyderabad, Kanpur, Nagpur, Pune
2024-09-30
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Aurangabad, Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2024-09-26
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-09-04
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugBHV-7000
Biohaven Therapeutics Ltd.
Phase 2
660
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-07-30
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Surat, Vadodara, Nagpur, Nashik, Pune, Jaipur, Kanpur, Ahmedabad
2024-07-19
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
DrugsFinerenone·Dapagliflozin
Colorado Prevention Center
Phase 3
1,500
Ahmedabad, Bangalore, Nagpur, New Delhi
2024-07-09
Recruiting
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm
NCT06240715Preterm, Infant Death
Nemours Children's Clinic
Not applicable
800
Belagavi, Chandrapur, Nagpur, Pune, Wardha, Jaipur, Hyderabad
2024-07-01
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi
2024-05-21
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugBHV-7000
Biohaven Therapeutics Ltd.
Phase 2/3
390
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-05-13
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Ahmedabad, Belagavi, Chandigarh, Faridabad, Kolkata, Nagpur, Pune
2024-05-08
Recruiting
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
NCT05795140Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals
Phase 3
65
Nagpur, Pune
2024-05-08
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bengaluru, Chandigarh, Delhi, Gurgaon, Mangaluru, Nagpur, New Delhi, Thiruvananthapuram
2024-04-16
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab Deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207Heart Failure, Systemic Inflammation
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
680
Vijayawada, Visakhapatnam, Vadodara, Belagavi, Bengaluru, Mysuru, Udupi, Nagpur
2024-04-01
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Guwahati, Allahฤbฤd, Kolkata, Bhubaneswar, Gujrฤt, Nagpur, New Delhi, Surat
2024-03-13
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugFinerenone
Colorado Prevention Center
Phase 3
5,200
Guntur, Vijayawada, Patna, Ahmedabad, Kochi, Nagpur, Nashik, New Delhi
2024-01-17
Recruiting
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
NCT06168019Influenza, COVID-19, SARS-COV-2 Infection, Other Respiratory Viruses
Boston University
Observational
10,000
Nagpur
2023-12-26
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Chandigarh, Hyderabad, Kochi, Nagpur, Nashik, New Delhi, Shimla, Thiruvananthapuram
2023-12-13
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Surat, Vadodara, Mysore, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune
2023-12-01
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Abiraterone acetate·Darolutamide·Enzalutamide
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Ahmedabad, Bangalore, Belagavi, Mysore, Nagpur, Nashik, New Delhi, Bikaner
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsXeloda·Epirubicin·Datopotamab Deruxtecan·Olaparib
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
700
Surat, Vadodara, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune, New Delhi
2023-11-10
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Active, closed
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
NCT06013969Generalized Pustular Psoriasis
DrugSpesolimab
LEO Pharma
Phase 4
42
Bikaner, Nagpur
2023-10-22
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
Bangalore, Nagpur, Pune, New Delhi, Hyderabad
2023-10-02
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Calicut, Jaipur, Lucknow, Madurai, Mohali, Nagpur, Nashik, New Delhi
2023-09-22
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-09-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Ahmedabad, Surat, Gurugram, Mumbai, Nagpur, NEW Delhi Delhi, Kolkata
2023-09-08
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2023-07-11
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Hyderabad, Ahmedabad, Faridabad, Hubli, Nagpur, Pune, Ajmer, Jaipur
2023-06-28
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
451
Ahmedabad, Chennai, Hyderabad, Kolkata, Nagpur, Nashik, New Delhi, Pune
2023-06-26
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Chandigarh, Bangalore, Kochi, Kolhฤpur, Nagpur, Pune, Bhubaneswar, Kolkata
2023-06-22
Recruiting
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
NCT05953584Sickle Cell Disease
DrugsEtavopivat·Hydroxyurea
Forma Therapeutics, Inc.
Phase 2
27
Raipur, Delhi, Gujarat, Maharashtra, Nagpur
2023-06-20
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
Guntur, Bangalore, Mysore, Nagpur, Pune
2023-06-05
Recruiting
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689Major Depressive Disorder
DrugLumateperone
Intra-Cellular Therapies, Inc.
Phase 3
470
Ahmedabad, Ajmer, Bฤrฤmati, Bikaner, Chandigarh, Guwahati, Kolhฤpur, Nagpur
2023-05-02
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi, Dehradun
2023-04-21
Recruiting
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
NCT05696613Primary Membranous Nephropathy
DrugRituximab
Cerium Pharmaceuticals, Inc.
Phase 3
148
Guntur, Nellore, Raipur, Nadiฤd, Belagavi, Nagpur, New Delhi, Chandigarh
2023-03-13
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
Ahmedabad, Hubli, Mysore, Nagpur, Vellore, Hyderabad, Secundarabad
2023-01-12
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Bhubaneswar, Chandigarh, Coimbatore, Guhawati, Mumbai, Nagpur, New Delhi, Secunderabad
2023-01-02
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
DrugAstegolimab
Hoffmann-La Roche
Phase 3
1,290
Hyderabad, Ahmedabad, Faridabad, Hubballi, Nagpur, Pune, Jaipur, Aligarh
2022-12-29
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
Surat, Bangalore, Bengaluru, Mysore, Nagpur, Nashik, Pune, Erode
2022-12-28
Active, closed
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
470
Ahmedabad, Bangalore, Chennai, Hyderabad, Jaipur, Nagpur, Nashik, Pune
2022-12-13
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugBLU-5937
Bellus Health Inc. - a GSK company
Phase 3
997
Belagavi, Faridabad, Nagpur, Nashik, Visakhapatnam
2022-12-05
Active, closed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
3,400
Surat, Belagavi, Kozhikode, Mumbai, Nagpur, Pune, Delhi, Chandigarh
2022-11-01
Active, closed
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries
NCT03657394Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
Nemours Children's Clinic
Not applicable
3,442
Belagavi, Nagpur, Pune, Chandrapur, Wardha, Jaipur
2022-10-17
Active, closed
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up
NCT03682042Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
Nemours Children's Clinic
Not applicable
3,442
Belagavi, Nagpur, Pune, Chandrapur, Wardha, Jaipur
2022-10-17
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Ahmedabad, Bikaner, Hyderabad, Lucknow, Ludhiana, Mumbai, Nagpur, New Delhi
2022-10-11
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Ahmedabad, Belagavi, Chandigarh, Kolkata, Nagpur, Pune
2022-08-22
Active, closed
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
NCT05297448Hepatic Encephalopathy
DrugRifaximin SSD
Bausch Health Americas, Inc.
Phase 3
466
Belagavi, Mangaluru, Nagpur, Nashik, Secunderabad, Sลซrat
2022-08-03
Active, closed
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
NCT05732805Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
Biocad
Phase 3
270
Faridabad, Mangalore, Mumbai, Nagpur, Nashik, New Delhi, Pune, Sangli
2022-08-02
Rows per page Showing 1–100 of 125
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/nagpur

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 125 of those studies with a site in Nagpur.

How many clinical trials are recruiting in Nagpur?

58 of the 125 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 7 have not yet opened recruitment, 56 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nagpur), 125 studies
PhaseStudiesRecruitingShare
Phase 3904372%
Phase 213610.4%
Not applicable715.6%
Phase 4624.8%
Phase 2/3423.2%
Observational221.6%
Phase 1221.6%
Phase 1/2100.8%

Most active sponsors

Lead sponsors with the most studies (Nagpur)
Lead sponsorStudiesRecruiting
AstraZeneca167
Eli Lilly and Company136
Bristol-Myers Squibb125
Novo Nordisk A/S95
Novartis Pharmaceuticals64
Sanofi60
Boehringer Ingelheim44
Akero Therapeutics, Inc32
All India Institute of Medical Sciences30
Hoffmann-La Roche31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.